Carnaculin tablets 50 for hypertension and circulatory disorders (kallidinogenase, kallikrein)
Product Code :
Availability : 11
General information on Japanese Carnaculin tablets 50 for hypertension and circulatory disorders (kallidinogenase, kallikrein)
Package details: 100 tablets
Manufacturer: Sanwa Kagaku Kenkyusho Co., Ltd., Japan
Active ingredient: kallidinogenase
Medical effect: Carnaculin tablets are effective for improvement of the following diseases and conditions:
- Meniere's disease,
- thromboangiitis obliterans,
- menopausal disorder,
- symptoms of circulatory disorder in the retina.
Contraindications and precautions: do not use for pregnant and breastfeeding women. Do not use for patients with bleeding such as immediately after cerebral bleeding.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration
For adults, take 1 tablet (50 units of the active ingredient) at a time, 3 times a day. The doctor in charge may adjust the dosage according to age or symptoms.
Please swallow the tablet without chewing or crushing.
How effective are Carnaculin tablets 50 from Japan for hypertension and circulatory disorders (kallidinogenase, kallikrein)?
Carnaculin tablets contain kallidinogenase, a glycoprotein derived from blood plasma, urine or some other human tissues. It works by processing kininogens in order to release bioactive kinins. By this, Carnaculin tablets regulate the kinin–kallikrein system, dilate the peripheral blood vessels and improve the blood flow.
Who should take Carnaculin tablets 50 from Japan?
Carnaculin tablets are effective for improvement of hypertension, Meniere's disease, thromboangiitis obliterans, menopausal disorder, and symptoms of circulatory disorder in the retina. Studies showed that kallidinogenase ameliorates neurological symptoms in stroke patients with few adverse effects (Yuanxiang Huang, Binglei Wang et al. “Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis”. Journal of International Medical Research, 2020,48(9): 300060520943452).